AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Use of Biologic Agents and Immunomodulators in Cutaneous Emergencies

Description

The discussion focuses on the use of biologic agents and immunomodulators in treating various cutaneous emergencies such as generalized pustular psoriasis, erythrodermic psoriasis, pyoderma gangrenosum, bullous pemphigoid, and toxic epidermal necrolysis. Generalized pustular psoriasis is highlighted as a severe condition with high mortality risk due to complications like sepsis. The speaker discusses the promising outcomes of a new drug, which showed significant efficacy in treating pustular psoriasis and pyoderma gangrenosum. Various biologics, including TNF inhibitors and IL-17 blockers, are evaluated for their effectiveness, with some showing rapid and substantial results, although there are concerns about their speed and adequacy. Erythrodermic psoriasis treatment strategies are discussed, emphasizing the importance of accurate diagnosis to avoid potential harm from inappropriate treatments. The transition to dupilumab for conditions like bullous pemphigoid is explained, showcasing its efficacy and quicker patient recovery times compared to traditional treatments like steroids. Lastly, the use of TNF blockers is recommended for timely healing in toxic epidermal necrolysis, suggesting a shift in treatment protocols based on emerging evidence. Overall, the talk underscores advancements in treating severe skin conditions with biologic therapy, emphasizing the importance of early intervention and tailored treatment approaches.

View more

Conclusions

  • Generalized pustular psoriasis is a severe condition with a significantly increased risk of mortality, often due to sepsis.
  • Deficiencies in interleukin-36 receptor antagonists are a common genetic factor in generalized pustular psoriasis.
  • Spesolimab is an effective treatment for generalized pustular psoriasis, demonstrating rapid and significant improvement in patients.
  • In a study, spesolimab showed a higher rate of skin clearance compared to placebo and a substantial reduction in flare occurrences in patients with a history of generalized pustular psoriasis.
  • Biologics like etanercept and infliximab have been used for generalized pustular psoriasis but may be less effective when compared with newer treatments like spesolimab.
  • Erythrodermic psoriasis requires accurate diagnosis, as treatment options can vary based on the correct identification of the condition.
  • Newer biologic therapies have demonstrated effectiveness but inadequate rapid response for severe variants of psoriasis, highlighting a need for more effective drugs.
  • Dupilumab is observed to not adequately treat cases of psoriatic erythroderma due to potential misdiagnosis, and its associations with new onset of syndromes such as Sézary syndrome are concerning.
  • Studies on pyoderma gangrenosum indicate a shift towards using TNF blockers as first-line therapies, and new drugs like spesolimab show promise.
  • Immunomodulators and biologic agents significantly change the management of cutaneous emergencies associated with psoriasis and other skin conditions.
  • Green MS, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996;34(5 Pt 2):911-4
  • Bakri FG, et al. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis. Scand J Infect Dis
  • Pouessel G, et al. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Pediatr Dermatol 2007;24:401-4
  • Sharkey MP, et al. Staphylococcal scalded skin syndrome complicating acute generalized pustular psoriasis. Australas J Dermatol 2002;43:199-201
  • Gottlieb AB, et al. EADV 2023, P2442. Sponsored by Boehringer Ingelheim
  • Marrakchi S, et al; Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620-8
  • Burns M, Orlowski M, Ho-Pham H, Elston C, Elewski B. New Onset Generalized Pustular Psoriasis Rapidly Improved with IL-36 Blockade. SKIN, 2023; 7:585-588
  • Bachelez H, et al. N Engl J Med. 2021;385:2431-2440; Trial of Spesolimab for Generalized Pustular Psoriasis
  • Bachelez H, et al. EADV 2018, Late-breaking news D3T01.1E Sponsored by Boehringer Ingelheim
  • Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Van Voorhees AS; National Psoriasis Foundation Medical Board. J Am Acad Dermatol. 2010;62(4):655-62
  • Thomas M, et al. Sezary syndrome - unmasked by cyclosporine. Int J Dermatol. 1998;37:957-8
  • Deepak P, et al. T-cell non-Hodgkin's lymphomas reported to the FDAAERS with tumor necrosis factor-alpha (TNF-a) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105
  • Chebani R, Lombart F, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2024 Jan 23;190(2):258-265.